Study of Chemotherapy Combination With Autologous Cytokine-Induced Killer Cell Immunotherapy to Treat Lung Cancer
Status:
Completed
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
This randomized, multicenter,open-label phase II/III study is to evaluate the effects of
chemotherapy combination with autologous cytokine-induced killer Cell immunotherapy in
patients with stage IIIb-IV squamous non-small-cell lung cancer
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital